Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Pediatrix Medical (MD) Income towards Parent Company (2016 - 2026)

Pediatrix Medical (MD) has disclosed Income towards Parent Company for 16 consecutive years, with $33.7 million as the latest value for Q4 2025.

  • Quarterly Income towards Parent Company rose 10.51% to $33.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $165.4 million through Dec 2025, up 266.94% year-over-year, with the annual reading at $165.4 million for FY2025, N/A changed from the prior year.
  • Income towards Parent Company for Q4 2025 was $33.7 million at Pediatrix Medical, down from $71.7 million in the prior quarter.
  • The five-year high for Income towards Parent Company was $71.7 million in Q3 2025, with the low at -$153.0 million in Q2 2024.
  • Average Income towards Parent Company over 4 years is $5.8 million, with a median of $6.4 million recorded in 2021.
  • The sharpest move saw Income towards Parent Company surged 5869.95% in 2021, then crashed 179.61% in 2022.
  • Over 4 years, Income towards Parent Company stood at $7.2 million in 2021, then fell by 21.77% to $5.7 million in 2022, then skyrocketed by 438.61% to $30.5 million in 2024, then rose by 10.51% to $33.7 million in 2025.
  • According to Business Quant data, Income towards Parent Company over the past three periods came in at $33.7 million, $71.7 million, and $39.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.